Ñî¹óåú´«Ã½Ò•îl

Merck said Monday it will stop developing both of the current formulations of the Covid-19 vaccines the company was working on, citing inadequate immune responses to the shots. Work will continue on at least one of the vaccines, which is being developed in partnership with the International AIDS Vaccine Initiative (IAVI), to see if using a different route of administration would improve how effective it is. (Herper and Branswell, 1/25)

Merck is halting development of its two COVID-19 vaccine candidates, saying that while the drugs seemed to be safe, they didn't generate enough of an immune response to effectively protect people against the coronavirus. Results of Phase 1 clinical studies showed that the two vaccine candidates — known as V590 and V591 — "were generally well tolerated, but the immune responses were inferior to those seen following natural infection and those reported for other SARS-CoV-2/COVID-19 vaccines," Merck said in a statement about its decision. (Chappell, 1/25)

The decision by U.S. pharmaceutical giant Merck to get out of the COVID-19 vaccine research business should have little direct impact on efforts to vaccinate Americans – and it's proof safety protocols are working, experts say. Developing a vaccine is challenging and laden with failures, so Merck’s announcement Monday that it was giving up development of two COVID-19 vaccines after poor results  wasn’t a complete surprise, said Dennis Carroll, who led the pandemic unit at the federal Agency for International Development for nearly 15 years. The real surprise, he said, is the success of the Pfizer and Moderna vaccines already widely distributed across the U.S. (Bacon, 1/25)

Merck & Co. called it quits on both of its COVID-19 vaccine candidates, citing lackluster efficacy data in phase 1. Meanwhile, Moderna is advancing a virus variant-specific booster shot into preclinical studies and a U.S. phase 1 trial. (Kansteiner, Sagonowsky, Liu and Hale, 1/25)